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EDITORIAL
Synchronous Colorectal Liver Metastases: Triumph
Of Prospective Randomized Trials Over Observational
Bias Leads To Paradigm Shift
Vijay P. Khatri, MBChB, FACS
University of California School of Medicine, Sacramento, CA
‘‘We can’t solve problems by using the same kind of
thinking we used when we created them.’’
Albert Einstein
The last one and a half decade has witnessed an exciting
era for the management of advanced colorectal cancer, with
emergence of effective combination chemotherapy, potent
biologic agents, surgical techniques for safe hepatic resec-
tion and ancillary procedures such as portal vein
embolization and radiofrequency ablation. Integration of
these various interventions within the context of a multi-
disciplinary approach has fostered an aggressive stance
amongst oncologists.1 This approach continues to be pushed
forward with attempts to ‘‘tease out’’ additional patients
who may become candidate for curative hepatic resection
and hence alter the natural history of their disease.2
In this issue, Reddy et al comprehensively review the
current evidence for outcomes in the management of syn-
chronous colorectal liver metastases (CRLM) and inquire
whether a paradigm shift is necessary.3 Let us examine some
of the controversial issues that the authors raise in this review
and then determine whether a paradigm change is justified.
The traditional approach to the management of the
asymptomatic primary tumor with synchronous CRLM has
been to resect it to avoid future obstruction, perforation or
bleeding. This notion is particularly evident for rectal
primaries where surgeons believe that at minimum a
diverting colostomy is necessary to prevent eventual
obstruction during systemic chemotherapy/chemoradiation.
Given that even primary tumors are now commonly con-
sidered quite responsive to current multiagent
chemotherapy, potential complications are an unlikely
event as evidenced by the report from the BRiTE registry.4
Additional evidence will hopefully become available from
the National Surgical Adjuvant Breast and Bowel Project
(NSABP) C-10, a phase II trial evaluating FOLFOX6 with
bevacizumab in patients who present with untreated pri-
mary colon cancer and concomitant metastatic disease not
considered surgically resectable for cure.
Downsizing to resectable disease has been extensively
investigated by the Paul Brousse group in France. Adam
et al reported their experience of a multimodality approach
where patients received multiple cycles of chemotherapy
and, if deemed resectable, then integrating a combination
of hepatic resection, resection of extrahepatic disease,
portal vein embolization, radiofrequency ablation, cryo-
therapy, two-stage hepatectomy, and repeat hepatectomy to
achieve cure.2 When one critically examines this most
aggressive approach for CRLM with an intention-to-treat
analysis, the percentage of long-term survivors at a mean
follow-up of 48.7 months was very low (3.5% alive and
2.2% alive without disease). This appears to be a long run
for a short slide. When the same data are used to claim that
chemotherapy will nullify the biologic effects of portal
lymph node metastases, the reservations expressed by
Wagman have to be echoed.5 Inoperable colorectal
metastases may be considered a declining entity, but when
one examines the published series on ‘‘conversion che-
motherapy’’, patient selection is an important variable and
it is clear that, the criteria for non-resectability not only
differed between the studies but were often poorly defined.
Until the report of the multi-institutional phase III trial
by Portier et al, there had been no clear evidence from a
randomized trial that adjuvant chemotherapy, either sys-
temic or by hepatic artery infusion, added benefit over
surgery alone. This trial was marred by slow accrual and
inadequate sample size (173 of the planned 200 patients
over a period of 10 years) but nonetheless did show
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improvement in disease-free survival with the now obso-
lete 5-fluorouracil (5_FU) and leucovorin.6 It thus offered
proof of concept for adjuvant chemotherapy in this patient
population. This trial was included in a pooled analysis by
Mitry et al that showed at best a marginal statistical sig-
nificance (median progression free survival and overall
survival) in favor of adjuvant chemotherapy with a 5-FU
bolus-based regimen after complete resection of CRLM.
The NSABP trial C-09, which randomly assigned patients
to either systemic capecitabine and oxaliplatin alone or
with alternating hepatic artery infusion of floxuridine after
resection of liver-only metastases, was designed to answer
an important question but the study was unfortunately
closed as a result of lack of patient accrual—what now
appears to be a common theme!
The value of perioperative chemotherapy was evaluated
by the phase III prospective randomized controlled trial
(PRCT) by Nordlinger et al.7 In this study, 364 patients
with up to four resectable liver metastases were randomly
assigned to either six cycles of fluorouracil, leucovorin, and
oxaliplatin (FOLFOX-4) before and six cycles after surgery
or to surgery alone. The results demonstrated the absolute
increase in rate of progression-free survival with periop-
erative chemotherapy at 3 years to be 7.3% (P = 0.058) in
randomly assigned patients, 8.1% in eligible patients
(P = 0.041), and 9.2% in patients undergoing resection
(P = 0.025). This benefit was countered by a significantly
increased postoperative complication rate in those patients
who received perioperative chemotherapy versus surgery
alone. These complications included serious ones such as
biliary fistula, hepatic failure, intra-abdominal infection,
and the need for re-operation. These active chemothera-
peutic agents when administered preoperatively have
indeed influenced the morbidity of hepatic resection, rais-
ing the important question, which needs to be answered in
a prospective trial: is adjuvant or neoadjuvant chemother-
apy less toxic to the liver? Indeed, an Intergroup US
multicenter prospective randomized phase III trial of per-
ioperative chemotherapy versus adjuvant chemotherapy in
resectable hepatic metastases is in the planning stage and
should be supported by the oncologists.
Most observational studies comparing outcomes of
synchronous CRLM to metachronous disease show that
survival is not dismal enough to justify a nihilistic
approach but we have to remember that the supporting
evidence is still Level III. Similarly, the debate about
simultaneous colorectal and hepatic resection for colorectal
live metastases is marred by the distinct absence of ran-
domized control trials: the evidence Level is II to III with
grade C recommendations.8 Almost all authors suggest that
a synchronous approach is feasible with the caveat that
careful selection of patient ought to be made by surgeons
specialized in colorectal and hepatobiliary surgery
functioning within a large-volume hospital. Here the adage
of Cady is relevant, ‘‘Tumor biology is king; and patient
selection is queen and technical details of surgical proce-
dures are the princes and princesses of the realm who
frequently try to overthrow the powerful forces of the king
and queen, usually to no avail, although with some tem-
porary apparent victories’’.9
Having examined the issues raised by the authors, what
we have here is a large body of observational studies
sprinkled with some prospective randomized trials that
forms the basis for suggesting a paradigm shift. Paradigm
is a trendy and an overused term, although current usage of
this term often has very little to do with what Kuhn put
forward. Paradigm shift occurs when Albert Einstein
enlightens us with the theory of special relativity, chal-
lenging the very concept of time and space to hold that
simple Newtonian mechanics are the same for all observers
in uniform motion. The same occurred when Bernard
Fisher so provocatively challenged Halstedian principles
by proposing that breast cancer can be considered a ‘‘sys-
temic disease at its inception’’.
When it comes to management of synchronous CRLM,
should we recommend a change in paradigm when there is
an overwhelming lack of Level I evidence? The answer is
no!- what we need is an ounce of judgment balanced with a
pound of commitment to prospective randomized trials.
Acceptance of exactly such ‘‘paradigm shifts’’ by the
oncology community, based upon low-level evidence,
fosters personal biases and results in poor accrual to PRCT
that are asking important questions. A concerted effort on
designing multi-institutional (adequately and realistically
powered) prospective randomized phase III clinical trials
and then completing them in a timely fashion with inter-
national cross-Atlantic cooperation is necessary to
counteract the problems of poor accrual. We do not need
yet another retrospective series. Whether it is a single
institutional report with 100 patients or a multi-institutional
retrospective review with 1000 patients, it does not change
the presence of bias nor the fact that the evidence it pro-
vides still remains Level III or at best Level II.
So, the real question is, how far do we extend the
indication for hepatic resection? The analogy that comes to
mind is the Frank-Starling Curve: an increase in preload
will increase the cardiac output until very high end dia-
stolic volumes are reached. At this point cardiac output will
not increase with any further increase in preload, and may
even decrease after a certain preload is reached. Similarly,
if we continue to expand the indications, there comes a
point where further extension only leads to inferior out-
come. Admittedly, surgery is still the one modality that
offers the potential of cure, but is likely reaching its limit of
benefit. Further enhancement of patient outcomes for this
patient population remains a challenge. Whether this might
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be achieved by better harnessing tumor biology, by precise
profiling of gene expression, by better disrupting dangerous
gene products, or by other methods, remain tantalizing
questions in oncology.
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